Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 17/20 | 0.47 |
| ▸ | NPY1R | P25929 | 11/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.47 |
| ▸ | NPY2R | P49146 | 7/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | TFPI | P10646 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26887003 | 0.93 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31670624 | 0.92 | TFPI (0.49) | NPY4RNPY1RNPY5RNPY2RKEAP1 | |
| SCHEMBL30905700 | 0.90 | RXFP1 (0.45) | NPY4RNPY1RNPY5RNPY2RKEAP1 | |
| SCHEMBL30543180 | 0.90 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29531964 | 0.89 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL26886898 | 0.89 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RKEAP1 | |
| SCHEMBL31303211 | 0.89 | NPY4R (0.48) | NPY4RNPY1RNPY5RNPY2RKEAP1 | |
| SCHEMBL31303214 | 0.89 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2RKEAP1 | |
| SCHEMBL22640925 | 0.89 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RKEAP1 | |
| SCHEMBL29938491 | 0.89 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206802-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-06-26 | — | — | US | disclosed |
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240117006-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | NPY4R 2780/4885NPY1R 2511/4885NPY5R 3842/4885 |
| US-20250206802-A1 | MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF | ITGA2B, ITGB1, ITGA1 | NPY4R 2780/4885NPY1R 2511/4885NPY5R 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.